SCHEMBL17809097

SCHEMBL17809097

CCCC(CNC(C)=O)N(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.36
CHRNB4 P30926 3/20 0.36
CHRNA4 P43681 3/20 0.36
PAOX Q6QHF9 1/20 0.34
CHRNA3 P32297 2/20 0.34
HDAC7 Q8WUI4 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
CHRM1 P11229 1/20 0.32
AKR1A1 P14550 1/20 0.32
CHRM3 P20309 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32
HRH1 P35367 1/20 0.32
DRD3 P35462 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4300740 0.89 PAOX (0.36) CHRNB2CHRNB4CHRNA4PAOXCHRNA3
SCHEMBL4300742 0.89 PAOX (0.36) CHRNB2CHRNB4CHRNA4PAOXCHRNA3
SCHEMBL14397158 0.74 PAOX (0.39) PAOXHDAC7HDAC8HDAC6HDAC9
SCHEMBL13950295 0.74 PAOX (0.39) PAOXHDAC7HDAC8HDAC6HDAC9
SCHEMBL24371945 0.72 PAOX (0.38) PAOXHDAC7HDAC8HDAC6HDAC9
SCHEMBL15132428 0.72 TDP1 (0.39) CHRNB2CHRNB4CHRNA4CHRNA3HDAC7
SCHEMBL8436494 0.72 TSHR (0.42) PAOXHDAC7HDAC8HDAC6HDAC9
SCHEMBL14392136 0.72 OPRD1 (0.32) OPRD1OPRK1
SCHEMBL9921630 0.71 EPHX1 (0.51) KDM4ETSHROPRM1OPRD1OPRK1
SCHEMBL18724552 0.71 ALDH1A1 (0.41) PAOXHDAC7HDAC8HDAC6HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656972-B2 Compounds for treatment of cystic fibrosis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-05-23 US disclosed
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS CFTR, ELANE, OTC CHRNB2 2806/4885CHRNB4 2679/4885CHRNA4 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.